CD4 and cancer: Taken together, these data suggest that circulating LAP-positive CD4+ Foxp3+ Tregs, rather than the general population of CD4+Foxp3+ T cells, can be used as a more accurate and specific marker for monitoring the immunological status of cancer patients.